Key result
TES expression correlates with tumor infiltration, metastasis, stage, and prognosis in high-Mena gastric cancer.
Why the study?
The tumor suppressive functions of TES and its interaction with Mena in gastric cancer were not fully understood.
TES functions as a Mena-dependent tumor suppressor in gastric cancer and may serve as a prognostic marker and potential therapeutic target.
TES may mark aggressive gastric cancer in high-Mena subsets; leaves open its value as a prognostic or therapeutic target in humans.
BACKGROUND: In our previous study, we identified a candidate tumor suppressor gene, testin LIM domain protein (TES), in primary gastric cancer (GC). TES contains three LIM domains, which are specific interacting regions for the cell adhesion and cytoskeleton regulatory proteins. Mena is a known cytoskeleton regulator that regulates the assembly of actin filaments and modulates cell adhesion and motility by interacting with Lamellipodin (Lpd). Therefore, we hypothesized that TES plays a role as tumor suppressor in GC through interacting with Mena. This study aimed to investigate the tumor suppressive functions of TES in GC. METHODS: We explored the tumor suppressive effect of TES in GC by in vitro cell proliferation assay, colony formation assay, cell cycle analysis, Transwell assays, and in vivo tumorigenicity and metastasis assays. The interaction of TES and Mena was investigated through immunoprecipitation-based mass spectrometry. We also analyzed the expression of TES and Mena in 172 GC specimens using immunohistochemistry and investigated the clinicopathological and prognostic significance of TES and Mena in GC. RESULTS: TES suppressed GC cell proliferation and colony formation, induced cell cycle arrest, and inhibited tumorigenicity in vitro. Additionally, it inhibited GC cell migration and invasion in vitro and suppressed metastasis in vivo. TES interacted with Mena, and inhibited the interaction of Mena with Lpd. Transwell assays suggested that TES suppressed migration and invasion of GC cells in a Mena-dependent fashion. In GC patients with high Mena expression, the expression of TES was associated with tumor infiltration (P = 0.005), lymph node metastasis (P = 0.003), TNM stage (P = 0.003), and prognosis (P = 0.010). However, no significant association was observed in GC patients with low Mena expression. CONCLUSIONS: We believe that TES functions as a Mena-dependent tumor suppressor. TES represents a valuable prognostic marker and potential target for GC treatment.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2019) studied Gastric cancer (n=172). TES expression vs. Low TES expression was evaluated on Prognosis in GC patients with high Mena expression (p=0.010). In gastric cancer patients with high Mena expression, TES expression was significantly associated with tumor infiltration, lymph node metastasis, TNM stage, and prognosis (P=0.010).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: